Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Methotrexate is used to treat autoimmune diseases and malignancies, including acute lymphoblastic leukemia (ALL). Inter-individual variation in clearance of methotrexate results in heterogeneous systemic exposure, clinical efficacy, and toxicity. In a genome-wide association study of children with A...
Gespeichert in:
| Veröffentlicht in: | Genome research Jg. 22; H. 1; S. 1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.01.2012
|
| Schlagworte: | |
| ISSN: | 1549-5469, 1549-5469 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Methotrexate is used to treat autoimmune diseases and malignancies, including acute lymphoblastic leukemia (ALL). Inter-individual variation in clearance of methotrexate results in heterogeneous systemic exposure, clinical efficacy, and toxicity. In a genome-wide association study of children with ALL, we identified SLCO1B1 as harboring multiple common polymorphisms associated with methotrexate clearance. The extent of influence of rare versus common variants on pharmacogenomic phenotypes remains largely unexplored. We tested the hypothesis that rare variants in SLCO1B1 could affect methotrexate clearance and compared the influence of common versus rare variants in addition to clinical covariates on clearance. From deep resequencing of SLCO1B1 exons in 699 children, we identified 93 SNPs, 15 of which were non-synonymous (NS). Three of these NS SNPs were common, with a minor allele frequency (MAF) >5%, one had low frequency (MAF 1%-5%), and 11 were rare (MAF <1%). NS SNPs (common or rare) predicted to be functionally damaging were more likely to be found among patients with the lowest methotrexate clearance than patients with high clearance. We verified lower function in vitro of four SLCO1B1 haplotypes that were associated with reduced methotrexate clearance. In a multivariate stepwise regression analysis adjusting for other genetic and non-genetic covariates, SLCO1B1 variants accounted for 10.7% of the population variability in clearance. Of that variability, common NS variants accounted for the majority, but rare damaging NS variants constituted 17.8% of SLCO1B1's effects (1.9% of total variation) and had larger effect sizes than common NS variants. Our results show that rare variants are likely to have an important effect on pharmacogenetic phenotypes. |
|---|---|
| AbstractList | Methotrexate is used to treat autoimmune diseases and malignancies, including acute lymphoblastic leukemia (ALL). Inter-individual variation in clearance of methotrexate results in heterogeneous systemic exposure, clinical efficacy, and toxicity. In a genome-wide association study of children with ALL, we identified SLCO1B1 as harboring multiple common polymorphisms associated with methotrexate clearance. The extent of influence of rare versus common variants on pharmacogenomic phenotypes remains largely unexplored. We tested the hypothesis that rare variants in SLCO1B1 could affect methotrexate clearance and compared the influence of common versus rare variants in addition to clinical covariates on clearance. From deep resequencing of SLCO1B1 exons in 699 children, we identified 93 SNPs, 15 of which were non-synonymous (NS). Three of these NS SNPs were common, with a minor allele frequency (MAF) >5%, one had low frequency (MAF 1%-5%), and 11 were rare (MAF <1%). NS SNPs (common or rare) predicted to be functionally damaging were more likely to be found among patients with the lowest methotrexate clearance than patients with high clearance. We verified lower function in vitro of four SLCO1B1 haplotypes that were associated with reduced methotrexate clearance. In a multivariate stepwise regression analysis adjusting for other genetic and non-genetic covariates, SLCO1B1 variants accounted for 10.7% of the population variability in clearance. Of that variability, common NS variants accounted for the majority, but rare damaging NS variants constituted 17.8% of SLCO1B1's effects (1.9% of total variation) and had larger effect sizes than common NS variants. Our results show that rare variants are likely to have an important effect on pharmacogenetic phenotypes.Methotrexate is used to treat autoimmune diseases and malignancies, including acute lymphoblastic leukemia (ALL). Inter-individual variation in clearance of methotrexate results in heterogeneous systemic exposure, clinical efficacy, and toxicity. In a genome-wide association study of children with ALL, we identified SLCO1B1 as harboring multiple common polymorphisms associated with methotrexate clearance. The extent of influence of rare versus common variants on pharmacogenomic phenotypes remains largely unexplored. We tested the hypothesis that rare variants in SLCO1B1 could affect methotrexate clearance and compared the influence of common versus rare variants in addition to clinical covariates on clearance. From deep resequencing of SLCO1B1 exons in 699 children, we identified 93 SNPs, 15 of which were non-synonymous (NS). Three of these NS SNPs were common, with a minor allele frequency (MAF) >5%, one had low frequency (MAF 1%-5%), and 11 were rare (MAF <1%). NS SNPs (common or rare) predicted to be functionally damaging were more likely to be found among patients with the lowest methotrexate clearance than patients with high clearance. We verified lower function in vitro of four SLCO1B1 haplotypes that were associated with reduced methotrexate clearance. In a multivariate stepwise regression analysis adjusting for other genetic and non-genetic covariates, SLCO1B1 variants accounted for 10.7% of the population variability in clearance. Of that variability, common NS variants accounted for the majority, but rare damaging NS variants constituted 17.8% of SLCO1B1's effects (1.9% of total variation) and had larger effect sizes than common NS variants. Our results show that rare variants are likely to have an important effect on pharmacogenetic phenotypes. Methotrexate is used to treat autoimmune diseases and malignancies, including acute lymphoblastic leukemia (ALL). Inter-individual variation in clearance of methotrexate results in heterogeneous systemic exposure, clinical efficacy, and toxicity. In a genome-wide association study of children with ALL, we identified SLCO1B1 as harboring multiple common polymorphisms associated with methotrexate clearance. The extent of influence of rare versus common variants on pharmacogenomic phenotypes remains largely unexplored. We tested the hypothesis that rare variants in SLCO1B1 could affect methotrexate clearance and compared the influence of common versus rare variants in addition to clinical covariates on clearance. From deep resequencing of SLCO1B1 exons in 699 children, we identified 93 SNPs, 15 of which were non-synonymous (NS). Three of these NS SNPs were common, with a minor allele frequency (MAF) >5%, one had low frequency (MAF 1%-5%), and 11 were rare (MAF <1%). NS SNPs (common or rare) predicted to be functionally damaging were more likely to be found among patients with the lowest methotrexate clearance than patients with high clearance. We verified lower function in vitro of four SLCO1B1 haplotypes that were associated with reduced methotrexate clearance. In a multivariate stepwise regression analysis adjusting for other genetic and non-genetic covariates, SLCO1B1 variants accounted for 10.7% of the population variability in clearance. Of that variability, common NS variants accounted for the majority, but rare damaging NS variants constituted 17.8% of SLCO1B1's effects (1.9% of total variation) and had larger effect sizes than common NS variants. Our results show that rare variants are likely to have an important effect on pharmacogenetic phenotypes. |
| Author | Cheng, Cheng Relling, Mary V Vattathil, Selina Rosner, Gary L Bruun, Gitte H Pui, Ching-Hon Evans, William E Giacomini, Kathleen M Fan, Yiping Sparreboom, Alex Mikkelsen, Torben S Ramsey, Laura B Treviño, Lisa R Corydon, Thomas J Yang, Wenjian Scheet, Paul |
| Author_xml | – sequence: 1 givenname: Laura B surname: Ramsey fullname: Ramsey, Laura B organization: Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA – sequence: 2 givenname: Gitte H surname: Bruun fullname: Bruun, Gitte H – sequence: 3 givenname: Wenjian surname: Yang fullname: Yang, Wenjian – sequence: 4 givenname: Lisa R surname: Treviño fullname: Treviño, Lisa R – sequence: 5 givenname: Selina surname: Vattathil fullname: Vattathil, Selina – sequence: 6 givenname: Paul surname: Scheet fullname: Scheet, Paul – sequence: 7 givenname: Cheng surname: Cheng fullname: Cheng, Cheng – sequence: 8 givenname: Gary L surname: Rosner fullname: Rosner, Gary L – sequence: 9 givenname: Kathleen M surname: Giacomini fullname: Giacomini, Kathleen M – sequence: 10 givenname: Yiping surname: Fan fullname: Fan, Yiping – sequence: 11 givenname: Alex surname: Sparreboom fullname: Sparreboom, Alex – sequence: 12 givenname: Torben S surname: Mikkelsen fullname: Mikkelsen, Torben S – sequence: 13 givenname: Thomas J surname: Corydon fullname: Corydon, Thomas J – sequence: 14 givenname: Ching-Hon surname: Pui fullname: Pui, Ching-Hon – sequence: 15 givenname: William E surname: Evans fullname: Evans, William E – sequence: 16 givenname: Mary V surname: Relling fullname: Relling, Mary V |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22147369$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtPwzAQhC1URFvgyBX5xiklfiSxuUHFS6pUicc5cuxNa9TYxXYq-PcEtUicZlbz7Uo7UzRy3gFCFySfEZKT61WYESrLUgwjOUITUnCZFbyUo39-jKYxfuR5zrgQJ2hMKeEVK-UE1S8qAN5BiH3E2nedd3inglUuRWwd3q5V6JT2K3CQrI43-HUxX5I7sqeSHXjlDO4grX0K8KUSYGPj1kf7G56h41ZtIpwf9BS9P9y_zZ-yxfLxeX67yDQXPGWsYEY0DWOtkHlFJFGUt4wq0whpilZVjYGq0LzSbS61NFASTTQIXQ0rYCQ9RVf7u9vgP3uIqe5s1LDZKAe-j7UknA3_UzaQlweybzow9TbYToXv-q8T-gOsfmaN |
| CitedBy_id | crossref_primary_10_1016_j_cotox_2020_07_003 crossref_primary_10_1007_s43440_021_00319_y crossref_primary_10_1200_JCO_2014_59_1636 crossref_primary_10_1016_j_blre_2015_01_001 crossref_primary_10_1002_pbc_30831 crossref_primary_10_1111_bcp_15956 crossref_primary_10_1016_j_tpr_2022_100115 crossref_primary_10_1111_bcp_12326 crossref_primary_10_1111_ddg_15537_g crossref_primary_10_1089_omi_2022_0097 crossref_primary_10_1158_1078_0432_CCR_12_3306 crossref_primary_10_1038_s41397_022_00288_2 crossref_primary_10_1186_s40246_024_00594_9 crossref_primary_10_1093_eurheartj_ehv116 crossref_primary_10_1111_cts_12879 crossref_primary_10_1002_jcph_721 crossref_primary_10_1016_S0140_6736_12_62187_4 crossref_primary_10_1002_wsbm_1199 crossref_primary_10_6064_2012_428139 crossref_primary_10_1038_s41397_019_0081_5 crossref_primary_10_1002_cpt_2122 crossref_primary_10_1111_ddg_15537 crossref_primary_10_2217_pgs_12_74 crossref_primary_10_1039_C9FO01168D crossref_primary_10_1182_blood_2014_12_580001 crossref_primary_10_1007_s10549_014_2910_1 crossref_primary_10_3390_ijms17091502 crossref_primary_10_1080_1744666X_2021_1968833 crossref_primary_10_1038_ejhg_2016_114 crossref_primary_10_2217_pgs_14_116 crossref_primary_10_1093_hmg_ddt588 crossref_primary_10_1128_AAC_02724_14 crossref_primary_10_1002_cpt_1957 crossref_primary_10_1097_FPC_0000000000000083 crossref_primary_10_1002_phar_2779 crossref_primary_10_1186_gm391 crossref_primary_10_1634_theoncologist_2015_0164 crossref_primary_10_1002_cpt_532 crossref_primary_10_1097_FPC_0000000000000245 crossref_primary_10_1007_s40142_013_0022_6 crossref_primary_10_1146_annurev_pharmtox_010510_100502 crossref_primary_10_1111_jth_13542 crossref_primary_10_3389_fphar_2022_1003812 crossref_primary_10_1002_wsbm_1509 crossref_primary_10_1080_17425255_2022_2113380 crossref_primary_10_1111_jebm_12302 crossref_primary_10_2217_pgs_14_106 crossref_primary_10_1007_s11899_017_0376_z crossref_primary_10_18632_oncotarget_9927 crossref_primary_10_3390_genes10030191 crossref_primary_10_1038_s41397_023_00300_3 crossref_primary_10_1080_17512433_2024_2307418 crossref_primary_10_1111_bph_16508 crossref_primary_10_1002_pbc_28858 crossref_primary_10_1111_epi_17228 crossref_primary_10_1016_j_jcyt_2024_02_002 crossref_primary_10_1002_cpt_1008 crossref_primary_10_1002_jcph_669 crossref_primary_10_1093_jnci_djad055 crossref_primary_10_1007_s00439_023_02628_z crossref_primary_10_3892_ol_2018_9147 crossref_primary_10_1002_pbc_25191 crossref_primary_10_1016_j_bcp_2024_116166 crossref_primary_10_1002_acr2_1008 crossref_primary_10_1124_mol_118_114314 crossref_primary_10_1038_s41598_023_43179_7 crossref_primary_10_1371_journal_pone_0077223 crossref_primary_10_3389_fphar_2019_00240 crossref_primary_10_3390_ph5080802 crossref_primary_10_1002_pbc_27637 crossref_primary_10_2217_pgs_15_2 crossref_primary_10_3390_pharmaceutics12090788 crossref_primary_10_1146_annurev_pharmtox_010617_053021 crossref_primary_10_1158_1078_0432_CCR_12_0761 crossref_primary_10_1111_cts_13130 crossref_primary_10_3389_fphar_2018_00020 crossref_primary_10_1146_annurev_med_053013_053944 crossref_primary_10_1038_clpt_2012_106 crossref_primary_10_2460_ajvr_79_5_538 crossref_primary_10_1111_cts_13773 crossref_primary_10_1586_17512433_2014_966811 crossref_primary_10_2174_1381612825666190329141003 crossref_primary_10_1097_FPC_0000000000000148 crossref_primary_10_1182_blood_2013_01_480335 crossref_primary_10_1016_j_phrs_2016_05_021 crossref_primary_10_1080_00498254_2019_1629043 crossref_primary_10_1038_s41375_022_01591_4 crossref_primary_10_1111_bcp_15915 crossref_primary_10_3390_pharmaceutics14040694 crossref_primary_10_3390_ijms18060639 crossref_primary_10_1038_tpj_2015_27 crossref_primary_10_1038_nrc3729 crossref_primary_10_1038_s41598_020_67312_y crossref_primary_10_1124_dmd_116_071183 crossref_primary_10_1002_cpt_2674 crossref_primary_10_1002_cpt_2557 crossref_primary_10_1080_10428194_2021_1913140 crossref_primary_10_1111_cts_13086 crossref_primary_10_1158_1078_0432_CCR_17_0429 crossref_primary_10_1111_bcp_14426 crossref_primary_10_1158_2767_9764_CRC_24_0332 crossref_primary_10_1038_clpt_2014_126 crossref_primary_10_1124_dmd_116_071860 crossref_primary_10_1038_clpt_2014_125 crossref_primary_10_1038_tpj_2014_63 crossref_primary_10_1007_s10928_014_9354_4 crossref_primary_10_1038_clpt_2012_120 crossref_primary_10_1038_s41598_017_08468_y crossref_primary_10_1124_dmd_113_055806 crossref_primary_10_1007_s40262_016_0450_z crossref_primary_10_1097_FPC_0b013e32835ff536 crossref_primary_10_2217_pgs_2023_0229 crossref_primary_10_3389_fphar_2019_01072 crossref_primary_10_3390_ijms160613760 crossref_primary_10_1016_j_leukres_2018_09_003 crossref_primary_10_3389_fphar_2015_00052 crossref_primary_10_1002_pbc_24623 crossref_primary_10_1182_blood_2012_07_440107 crossref_primary_10_1002_cpt_2721 crossref_primary_10_1002_pbc_27618 crossref_primary_10_1016_j_ejps_2022_106246 crossref_primary_10_3390_pharmaceutics15102473 crossref_primary_10_1038_s41397_018_0047_z crossref_primary_10_1002_em_21799 crossref_primary_10_1111_bcp_15506 crossref_primary_10_1111_bcp_13207 crossref_primary_10_1016_j_biopha_2021_111456 crossref_primary_10_1038_s41598_018_29351_4 crossref_primary_10_1038_nrg3523 crossref_primary_10_1097_FPC_0000000000000202 crossref_primary_10_3390_ijms25084426 crossref_primary_10_1186_s13104_018_3469_4 crossref_primary_10_1007_s11684_015_0381_3 crossref_primary_10_1111_bcp_14407 crossref_primary_10_1177_10781552221076456 crossref_primary_10_3389_fphar_2024_1423214 crossref_primary_10_1002_cpt_2053 crossref_primary_10_1016_j_pharmthera_2019_01_002 crossref_primary_10_1097_FTD_0b013e3182a94e65 crossref_primary_10_1097_MPH_0000000000001816 crossref_primary_10_2217_pme_14_56 crossref_primary_10_3390_metabo12121159 crossref_primary_10_1016_j_pharmthera_2022_108268 crossref_primary_10_1080_03602532_2024_2364591 crossref_primary_10_2217_pgs_13_193 crossref_primary_10_1002_gepi_21740 crossref_primary_10_2217_pgs_14_144 crossref_primary_10_1002_cpt_3623 crossref_primary_10_1016_j_clinthera_2012_06_022 crossref_primary_10_1038_clpt_2012_57 crossref_primary_10_3389_fgene_2014_00323 crossref_primary_10_1517_17425255_2014_893294 crossref_primary_10_1016_j_ejps_2023_106416 crossref_primary_10_1080_03009742_2020_1818821 crossref_primary_10_1097_BS9_0000000000000142 crossref_primary_10_1016_j_tips_2016_08_003 crossref_primary_10_3389_fphar_2019_00209 crossref_primary_10_1016_j_yamp_2022_05_003 crossref_primary_10_1007_s11095_021_03107_8 crossref_primary_10_1038_clpt_2013_9 crossref_primary_10_1038_s41416_021_01589_2 crossref_primary_10_1186_s12920_019_0527_2 crossref_primary_10_1002_phar_4638 crossref_primary_10_1080_17425255_2017_1246532 crossref_primary_10_3390_cancers13112837 crossref_primary_10_1038_clpt_2012_51 crossref_primary_10_1038_clpt_2013_214 crossref_primary_10_1080_17474086_2020_1685866 crossref_primary_10_1016_j_semcancer_2020_10_013 crossref_primary_10_1007_s13238_015_0148_2 crossref_primary_10_1016_j_ejps_2019_01_024 crossref_primary_10_1016_j_tig_2012_06_008 crossref_primary_10_3390_genes11040468 crossref_primary_10_1002_cpt_315 crossref_primary_10_3389_fphar_2023_1130548 crossref_primary_10_1007_s40262_015_0267_1 crossref_primary_10_1002_cpt_2429 crossref_primary_10_1002_cpt_2705 crossref_primary_10_1007_s40262_015_0328_5 crossref_primary_10_1186_s40246_023_00546_9 crossref_primary_10_1038_s41397_022_00274_8 crossref_primary_10_1038_nrg3352 crossref_primary_10_1016_j_critrevonc_2018_04_002 crossref_primary_10_2217_pgs_12_44 crossref_primary_10_1097_CAD_0000000000001125 crossref_primary_10_1182_blood_2012_08_452839 crossref_primary_10_2217_pgs_13_17 crossref_primary_10_1186_gm405 crossref_primary_10_1080_17425255_2024_2332366 crossref_primary_10_1634_theoncologist_2017_0243 crossref_primary_10_1002_cpt_1463 crossref_primary_10_1038_s41397_018_0035_3 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1101/gr.129668.111 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry Biology |
| EISSN | 1549-5469 |
| ExternalDocumentID | 22147369 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA36401 – fundername: NCI NIH HHS grantid: R01 CA036401 – fundername: NCI NIH HHS grantid: CA 21765 – fundername: NIGMS NIH HHS grantid: U01 GM092666 – fundername: NHLBI NIH HHS grantid: U01 HL65899 – fundername: NCI NIH HHS grantid: R37 CA036401 – fundername: NCI NIH HHS grantid: P30 CA021765 – fundername: NHLBI NIH HHS grantid: U01 HL065899 – fundername: NIGMS NIH HHS grantid: U01 GM92666 |
| GroupedDBID | --- .GJ 18M 29H 2WC 39C 4.4 53G 5GY 5RE 5VS AAYOK AAZTW ABDIX ABDNZ ACGFO ACYGS ADBBV ADNWM AEILP AENEX AHPUY AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE IH2 K-O KQ8 MV1 NPM R.V RCX RHF RHI RNS RPM RXW SJN TAE TR2 VH1 W8F WOQ YKV ZCG ZGI ZXP 7X8 ACLKE |
| ID | FETCH-LOGICAL-c484t-353d8bb33f8907191a24f32adb89d5fa7bde75c47cf09c9de61c1ce8c733fed92 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 211 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000298854200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1549-5469 |
| IngestDate | Wed Oct 01 14:53:52 EDT 2025 Wed Feb 19 01:49:19 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c484t-353d8bb33f8907191a24f32adb89d5fa7bde75c47cf09c9de61c1ce8c733fed92 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://genome.cshlp.org/content/22/1/1.full.pdf |
| PMID | 22147369 |
| PQID | 914300023 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_914300023 pubmed_primary_22147369 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-01-01 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 01 year: 2012 text: 2012-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Genome research |
| PublicationTitleAlternate | Genome Res |
| PublicationYear | 2012 |
| References | 16532393 - Am J Hum Genet. 2006 Apr;78(4):629-44 6141424 - Lancet. 1984 Feb 18;1(8373):359-62 19022939 - Drug Metab Dispos. 2009 Feb;37(2):277-81 23438881 - Pharmacogenomics. 2013 Mar;14(4):357-60 15159445 - J Pharmacol Exp Ther. 2004 Oct;311(1):139-46 11254454 - Am J Hum Genet. 2001 Apr;68(4):978-89 21116304 - Nat Rev Genet. 2011 Jan;12(1):69-73 17108811 - Pharmacogenet Genomics. 2006 Dec;16(12):873-9 21047260 - Annu Rev Genet. 2010;44:293-308 11477075 - J Biol Chem. 2001 Sep 21;276(38):35669-75 21129725 - Am J Hum Genet. 2010 Dec 10;87(6):790-801 9468466 - N Engl J Med. 1998 Feb 19;338(8):499-505 22838946 - Pharmacogenomics. 2012 Jul;13(9):993-4 21457907 - Am J Hum Genet. 2011 Apr 8;88(4):458-68 17473846 - Clin Pharmacol Ther. 2007 Dec;82(6):726-33 15251979 - Blood. 2004 Nov 1;104(9):2690-6 21387541 - Pediatr Blood Cancer. 2011 Oct;57(4):612-9 19581920 - Pharmacogenomics J. 2009 Oct;9(5):291-305 15961978 - Clin Pharmacol Ther. 2005 Jun;77(6):468-78 10835412 - Genetics. 2000 Jun;155(2):945-59 18154446 - Pharmacogenomics. 2008 Jan;9(1):19-33 19901119 - J Clin Oncol. 2009 Dec 10;27(35):5972-8 10644574 - Am J Physiol Gastrointest Liver Physiol. 2000 Jan;278(1):G156-64 11337480 - Genome Res. 2001 May;11(5):863-74 20054350 - Leukemia. 2010 Apr;24(4):894-6 21060006 - Hypertension. 2010 Dec;56(6):1069-76 15390262 - Proteins. 2004 Dec 1;57(4):811-9 15970799 - Pharmacogenet Genomics. 2005 Jul;15(7):513-22 19835554 - Curr Pharm Des. 2010;16(2):220-30 18509313 - Nat Genet. 2008 Jun;40(6):695-701 15564882 - Pharmacogenetics. 2004 Nov;14(11):749-57 11375950 - Gastroenterology. 2001 Jun;120(7):1689-99 19553647 - N Engl J Med. 2009 Jun 25;360(26):2730-41 16551372 - BMC Bioinformatics. 2006;7:166 20821001 - J Membr Biol. 2010 Aug;236(3):279-90 21151126 - Nat Genet. 2011 Jan;43(1):43-7 20657596 - Nat Genet. 2010 Aug;42(8):684-7 20354512 - Nat Methods. 2010 Apr;7(4):248-9 21058334 - Genet Epidemiol. 2010 Dec;34(8):816-34 16449388 - Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1810-5 21457909 - Am J Hum Genet. 2011 Apr 8;88(4):440-9 15226675 - Pharmacogenetics. 2004 Jul;14(7):429-40 15608127 - Drug Metab Dispos. 2005 Mar;33(3):434-9 15842561 - Br J Clin Pharmacol. 2005 May;59(5):602-4 3456079 - N Engl J Med. 1986 Feb 20;314(8):471-7 20940738 - Nat Rev Genet. 2010 Nov;11(11):773-85 20644253 - J Clin Invest. 2010 Aug;120(8):2942-52 |
| References_xml | – reference: 11477075 - J Biol Chem. 2001 Sep 21;276(38):35669-75 – reference: 15226675 - Pharmacogenetics. 2004 Jul;14(7):429-40 – reference: 16551372 - BMC Bioinformatics. 2006;7:166 – reference: 21457909 - Am J Hum Genet. 2011 Apr 8;88(4):440-9 – reference: 3456079 - N Engl J Med. 1986 Feb 20;314(8):471-7 – reference: 19553647 - N Engl J Med. 2009 Jun 25;360(26):2730-41 – reference: 17473846 - Clin Pharmacol Ther. 2007 Dec;82(6):726-33 – reference: 15159445 - J Pharmacol Exp Ther. 2004 Oct;311(1):139-46 – reference: 15842561 - Br J Clin Pharmacol. 2005 May;59(5):602-4 – reference: 10644574 - Am J Physiol Gastrointest Liver Physiol. 2000 Jan;278(1):G156-64 – reference: 21151126 - Nat Genet. 2011 Jan;43(1):43-7 – reference: 15564882 - Pharmacogenetics. 2004 Nov;14(11):749-57 – reference: 11337480 - Genome Res. 2001 May;11(5):863-74 – reference: 18509313 - Nat Genet. 2008 Jun;40(6):695-701 – reference: 19581920 - Pharmacogenomics J. 2009 Oct;9(5):291-305 – reference: 9468466 - N Engl J Med. 1998 Feb 19;338(8):499-505 – reference: 15961978 - Clin Pharmacol Ther. 2005 Jun;77(6):468-78 – reference: 21116304 - Nat Rev Genet. 2011 Jan;12(1):69-73 – reference: 15251979 - Blood. 2004 Nov 1;104(9):2690-6 – reference: 15390262 - Proteins. 2004 Dec 1;57(4):811-9 – reference: 20657596 - Nat Genet. 2010 Aug;42(8):684-7 – reference: 20054350 - Leukemia. 2010 Apr;24(4):894-6 – reference: 21060006 - Hypertension. 2010 Dec;56(6):1069-76 – reference: 23438881 - Pharmacogenomics. 2013 Mar;14(4):357-60 – reference: 22838946 - Pharmacogenomics. 2012 Jul;13(9):993-4 – reference: 11254454 - Am J Hum Genet. 2001 Apr;68(4):978-89 – reference: 21387541 - Pediatr Blood Cancer. 2011 Oct;57(4):612-9 – reference: 17108811 - Pharmacogenet Genomics. 2006 Dec;16(12):873-9 – reference: 20354512 - Nat Methods. 2010 Apr;7(4):248-9 – reference: 11375950 - Gastroenterology. 2001 Jun;120(7):1689-99 – reference: 6141424 - Lancet. 1984 Feb 18;1(8373):359-62 – reference: 20940738 - Nat Rev Genet. 2010 Nov;11(11):773-85 – reference: 21457907 - Am J Hum Genet. 2011 Apr 8;88(4):458-68 – reference: 21129725 - Am J Hum Genet. 2010 Dec 10;87(6):790-801 – reference: 20821001 - J Membr Biol. 2010 Aug;236(3):279-90 – reference: 10835412 - Genetics. 2000 Jun;155(2):945-59 – reference: 16532393 - Am J Hum Genet. 2006 Apr;78(4):629-44 – reference: 19022939 - Drug Metab Dispos. 2009 Feb;37(2):277-81 – reference: 16449388 - Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1810-5 – reference: 18154446 - Pharmacogenomics. 2008 Jan;9(1):19-33 – reference: 15608127 - Drug Metab Dispos. 2005 Mar;33(3):434-9 – reference: 21047260 - Annu Rev Genet. 2010;44:293-308 – reference: 20644253 - J Clin Invest. 2010 Aug;120(8):2942-52 – reference: 21058334 - Genet Epidemiol. 2010 Dec;34(8):816-34 – reference: 19835554 - Curr Pharm Des. 2010;16(2):220-30 – reference: 19901119 - J Clin Oncol. 2009 Dec 10;27(35):5972-8 – reference: 15970799 - Pharmacogenet Genomics. 2005 Jul;15(7):513-22 |
| SSID | ssj0003488 |
| Score | 2.4974732 |
| Snippet | Methotrexate is used to treat autoimmune diseases and malignancies, including acute lymphoblastic leukemia (ALL). Inter-individual variation in clearance of... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1 |
| SubjectTerms | Adolescent Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - pharmacokinetics Child Child, Preschool Clinical Trials as Topic Cohort Studies Exons Female Haplotypes Humans Infant Male Methotrexate - administration & dosage Methotrexate - pharmacokinetics Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Organic Anion Transporters - genetics Organic Anion Transporters - metabolism Pharmacogenetics - methods Polymorphism, Single Nucleotide Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism Solute Carrier Organic Anion Transporter Family Member 1b1 |
| Title | Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22147369 https://www.proquest.com/docview/914300023 |
| Volume | 22 |
| WOSCitedRecordID | wos000298854200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT-MwELZ4Ci7L8lgoL_mAuBka24kdLgiqRRygi3hIvUWOPUE9bFqatoJ_z9hJuyfEYS9RDnES2xPPfOMv8xFyEjtAx64Ma7dBMBlby3IJlsW2SHiecF7kNohNqG5X93rpQ8PNqRpa5WxNDAu1G1ifIz9P0bGH6iyXwzfmRaP85mqjoLFIlgVGMt6oVe9fsXAhg-ykL0LGYoSB8xKb0fnr6AwdXZJov2R8HVwGJ3Oz8Z-v95P8aKJLelWbwyZZgHKLbF-ViKz_ftBTGvieIZG-RVavZ2drnZnq2zbJHs0IqOdqTCqKj8Yb0yniaU-Xof2SDptS12h3_vfH6oI-3XX-RNdRfZWfZmpKR4My9XgE7xjLUtefk8N2yMvN7-fOLWtEGJiVWo6ZiIXTeS5EoRFHI7ozXBaCG5fr1MWFUbkDFVupbNFObeogiWxkQVuFTcCl_BdZKgcl7BEqUukUAHADVtooMUboGIGwzhUajGu3CJ2NbYa99jsXpoTBpMrmo9siu_X8ZMO6GEfGvdCSSNL97xsfkHUMd3idQDkkywV-4HBEVux03K9Gx8F48Nh9uP8EeSXQng |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rare+versus+common+variants+in+pharmacogenetics%3A+SLCO1B1+variation+and+methotrexate+disposition&rft.jtitle=Genome+research&rft.au=Ramsey%2C+Laura+B&rft.au=Bruun%2C+Gitte+H&rft.au=Yang%2C+Wenjian&rft.au=Trevi%C3%B1o%2C+Lisa+R&rft.date=2012-01-01&rft.eissn=1549-5469&rft.volume=22&rft.issue=1&rft.spage=1&rft_id=info:doi/10.1101%2Fgr.129668.111&rft_id=info%3Apmid%2F22147369&rft_id=info%3Apmid%2F22147369&rft.externalDocID=22147369 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-5469&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-5469&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-5469&client=summon |